Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients

References

• Xia L, Wu B, Fu Z, et al. Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies. Oncotarget. 2015;6(19):17354‒17365. doi:10.18632/oncotarget.v6i19
   Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 Mutations in Gliomas. N Engl J Med. 2009;360:765‒773. doi:10.1056/NEJMoa0808710
   PubMedGoogle Scholar
• Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469‒474. doi:10.1007/s00401-009-0561-9
   Web of Science ®Google Scholar
• Dang L, White DW, Gross S, et al. Cancer associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739‒744. doi:10.1038/nature08617
   PubMed Web of Science ®Google Scholar
• Molenaar RJ, Radivoyevitch T, Maciejewski JP, et al. The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Biochim Biophys Acta. 2014;1846(2):326‒341.
   Web of Science ®Google Scholar
• Zdzisińska B, Żurek A, Kandefer-Szerszeń M. Alpha-ketoglutarate as a molecule with pleiotropic activity: well-known and novel possibilities of therapeutic use. Arch Immunol Ther Exp. 2017;65:21‒36. doi:10.1007/s00005-016-0406-x
   PubMed Web of Science ®Google Scholar
• Siddiq A. Hypoxia inducible factor prolyl 4-hydroxylase enzymes: center stage in the battle against hypoxia, metabolic compromise and oxidative stress. Neurochem Res. 2007;32(4–5):931‒946. doi:10.1007/s11064-006-9136-5
   PubMed Web of Science ®Google Scholar
• Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5(5):378‒389. doi:10.1016/j.apsb.2015.05.007
   PubMed Web of Science ®Google Scholar
• Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1 alpha. Science. 2009;324:261‒265. doi:10.1126/science.1170944
   Web of Science ®Google Scholar
• Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17‒30. doi:10.1016/j.ccr.2010.12.014
   Web of Science ®Google Scholar
• Koivunen P, Lee S, Duncan CG, et al. Transformation by the (R)-enantiomer of 2- hydroxyglutarate linked to EGLN activation. Nature. 2012;483:484‒488. doi:10.1038/nature10843
   PubMed Web of Science ®Google Scholar
• Balamurugan K. HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int J Cancer. 2016;138(5):1058‒1066. doi:10.1002/ijc.29519
   PubMed Web of Science ®Google Scholar
• Noman MZ, Messai Y, Carré T, et al. Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response. Crit Rev Immunol. 2011;31:357‒377. doi:10.1615/CritRevImmunol.v31.i5
   PubMed Web of Science ®Google Scholar
• Fossati G, Ricevuti G, Edwards SW, Walker C, Dalton A, Rossi ML. Neutrophil infiltration into human gliomas. Acta Neuropathol. 1999;98(4):349‒354. doi:10.1007/s004010051093
   PubMed Web of Science ®Google Scholar
• Liang J, Piao Y, Holmes L, et al. Neutrophils promote the malignant glioma phenotype through S100A4. Clin Cancer Res. 2014;20(1):187‒198. doi:10.1158/1078-0432.CCR-13-3045
   Web of Science ®Google Scholar
• Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol. 2013;23:200‒207. doi:10.1016/j.semcancer.2013.02.001
   PubMed Web of Science ®Google Scholar
• Menter DG, Tucker SC, Kopetz S, et al. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev. 2014;33(1):231‒269.
   PubMed Web of Science ®Google Scholar
• Amankulor NM, Kim Y, Arora S, et al. Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev. 2017;31:1‒13. doi:10.1101/gad.294991.116
   PubMed Web of Science ®Google Scholar
• Unruh D, Schwarze SR, Khoury L, et al. Mutant IDH1 and thrombosis in gliomas. Acta Neuropathol. 2016;132(6):917‒930. doi:10.1007/s00401-016-1620-7
   PubMed Web of Science ®Google Scholar
• Zhou X, Du Y, Huang Z, et al. Prognostic value of PLR in various cancers: a meta-analysis. PLoS One. 2014;9(6):e101119. doi:10.1371/journal.pone.010111924968121
   PubMed Web of Science ®Google Scholar
• Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J. 2009;32:471‒482.
   Google Scholar
• Hu L, Li M, Ding Y, et al. Prognostic value of RDW in cancers: a systematic review and meta-analysis. Oncotarget. 2017;8(9):16027‒16035.
   Google Scholar
• Auezova R, Ryskeldiev N, Doskaliev A, et al. Association of preoperative levels of selected blood inflammatory markers with prognosis in gliomas. OncoTargets Ther. 2016;9:6111‒6117. doi:10.2147/OTT
   PubMed Web of Science ®Google Scholar
• Tham T, Bardash Y, Herman SW, Costantino PD. Neutrophil-to-lymphocyte ratio as a prognostic indicator in head and neck cancer: A systematic review and meta-analysis. Head Neck. 2018;40(11):2546‒2557. doi:10.1002/hed.25324
   Web of Science ®Google Scholar
• Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1204–1212. doi:10.1158/1055-9965.EPI-14-012924793958
   PubMed Web of Science ®Google Scholar
• Zhang F, Chen Z, Wang P, Hu X, Gao Y, He J. Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients. Tumor Biol. 2016;37:9323–9331. doi:10.1007/s13277-015-4774-3
   PubMedGoogle Scholar
• Sun Z, Ju Y, Han F, Sun X, Wang F. Clinical implications of pretreatment inflammatory biomarkers as independent prognostic indicators in prostate cancer. J Clin Lab Anal. 2018;32(3):e22277. doi:10.1002/jcla.2018.32.issue-3
   PubMed Web of Science ®Google Scholar
• Jin Y, Shi X, Shi L, et al. Prognostic value of circulating C-reactive protein levels in patients with non-small cell lung cancer: A systematic review with meta-analysis. J Cancer Res Ther. 2014;10(7):160‒166.
   Web of Science ®Google Scholar
• Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. doi:10.1093/jnci/dju06124875653
   PubMedGoogle Scholar
• Kuang D, Zhao Q, Wu Y, et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol. 2011;54:948‒955. doi:10.1016/j.jhep.2010.08.041
   PubMed Web of Science ®Google Scholar
• Trellakis S, Bruderek K, Dumitru C, et al. Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. Int J Cancer. 2011;129:2183‒2193. doi:10.1002/ijc.v129.9
   Web of Science ®Google Scholar
• Wang J, Jia Y, Wang N, et al. The clinical significance of tumor-infiltrating neutrophils and neutrophil-to-CD8+ lymphocyte ratio in patients with resectable esophageal squamous cell carcinoma. J Transl Med. 2014;12(1):7. doi:10.1186/1479-5876-12-724397835
   PubMedGoogle Scholar
• Sagiv JY, Michaeli J, Assi S, et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 2015;10:562‒573. doi:10.1016/j.celrep.2014.12.039
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas and lymphomas. Cancer Res. 2009;69(13):5383‒5391. doi:10.1158/0008-5472.CAN-08-3660
   Web of Science ®Google Scholar
• Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253‒268. doi:10.1038/nri3175
   PubMed Web of Science ®Google Scholar
• Duncan CG, Barwick BG, Jin G, et al. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res. 2012;22:2339–2355. doi:10.1101/gr.123497.11122899282
   PubMed Web of Science ®Google Scholar
• Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479–483. doi:10.1038/nature1086622343889
   PubMed Web of Science ®Google Scholar
• Miroshnikova YA, Mouw JK, Barnes JM, et al. Tissue mechanics promote IDH1-dependent HIF1α–tenascin C feedback to regulate glioblastoma aggression. Nat Cell Biol. 2016;18(12):1336–1345. doi:10.1038/ncb344327820599
   PubMed Web of Science ®Google Scholar
• Chesnelong C, Chaumeil MM, Blough MD, et al. Lactate dehydrogenase A silencing in IDH mutant gliomas. Neuro Oncol. 2014;16(5):686‒695. doi:10.1093/neuonc/nou085
   PubMed Web of Science ®Google Scholar
• Price SJ, Allinson K, Liu H, et al. Less invasive phenotype found in isocitrate dehydrogenase-mutated glioblastomas than in isocitrate dehydrogenase wild-type glioblastomas: a diffusion-tensor imaging study. Radiology. 2017;283(1):215‒221. doi:10.1148/radiol.2016152679
   PubMed Web of Science ®Google Scholar
• Mezouar S, Frère C, Darbousset R, et al. Role of platelets in cancer and cancer-associated thrombosis: experimental and clinical evidences. Thromb Res. 2016;139:65‒76. doi:10.1016/j.thromres.2016.01.006
   PubMed Web of Science ®Google Scholar
• Lam FW, Vijayan KV, Rumbaut RE. Platelets and their interactions with other immune cells. Compr Physiol. 2015;5(3):1265‒1280.
   PubMed Web of Science ®Google Scholar
• Pitchforda S, Pan D, Welch HCE. Platelets in neutrophil recruitment to sites of inflammation. Curr Opin Hematol. 2017;24:23‒31.
   Web of Science ®Google Scholar
• Zuchtriegel G, Uhl B, Puhr-Westerheide D, et al. Platelets guide leukocytes to their sites of extravasation. PLoS Biol. 2016;14(5):e1002459. doi:10.1371/journal.pbio.100245927152726
   PubMed Web of Science ®Google Scholar
• Strojnik T, Šmigoc T, Lah TT. Prognostic value of erythrocyte sedimentation rate and C-reactive protein in the blood of patients with glioma. Anticancer Res. 2014;34:339‒348.
   PubMed Web of Science ®Google Scholar
• Su C, Liao LZ, Song Y, et al. The role of red blood cell distribution width in mortality and cardiovascular risk among patients with coronary artery diseases: a systematic review and meta-analysis. J Thorac Dis. 2014;6(10):1429‒1440.
   Web of Science ®Google Scholar
• Shinko D, Diakos CI, Clarke SJ, Charles KA. Cancer-related systemic inflammation: the challenges and therapeutic opportunities for personalized medicine. Clin Pharmacol Ther. 2017;102(4):599‒610. doi:10.1002/cpt.789
   PubMed Web of Science ®Google Scholar
• Rossi JF, Négrier S, James ND, et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer. 2010;103(8):1154‒1162. doi:10.1038/sj.bjc.6605822
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen JQ, Xie L, et al. Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Med. 2014;12:55. doi:10.1186/s12916-014-0141-224678716
   PubMed Web of Science ®Google Scholar